**NOT FOR RELEASE UNTIL JAN 15, 2021**

**For more information:**

**Sharon Polk**

**Red Folder Consulting**

**913-221-5834**

**NRC guidelines pave the way for use of Synovetin OA® in dogs**

*Dogs with elbow arthritis are jumping for joy*

Buford, Georgia -- Nearly 25% of US dogs suffer from osteoarthritis1, with current treatments requiring daily administration to provide short-term relief. The Nuclear Regulatory Commission (NRC) recently issued licensing guidelines for the use of Synovetin OA®, a new veterinary device administered via intra-articular injection and intended to reduce synovitis and associated pain of canine elbow joints afflicted with osteoarthritis. Clinical trial data demonstrated Synovetin OA relieves pain and inflammation and improves mobility for up to one year. The NRC guidelines, issued to all relevant regulatory agencies, establish a protocol for veterinary practices interested in offering this innovative product to their patients. Synovetin OA was developed by Exubrion Therapeutics®.

“For dogs with chronic elbow pain, Synovetin OA is a new, convenient, long-lasting and safe option,” according to Dr. John Donecker, Exubrion’s chief veterinary officer. “Synovetin OA puts the treatment right where it’s needed and offers up to a full year of relief.”

Synovetin OA breaks the cycle of pain with just one treatment, clinically improving mobility and providing documented relief for up to a year. The active agent of Synovetin OA is Tin-117m, a unique conversion electron radiotherapeutic. Synovetin OA:

* Reduces synovitis and relieves chronic canine elbow OA pain
* Targets and eliminates (or deactivates) pro-inflammatory macrophages and synoviocytes, the key drivers of pain and inflammation
* Is administered just once a year, if needed
* No clinically significant systemic or local side effects were observed during clinical trials
* Is a minimally invasive outpatient procedure
* Can be used as part of a multimodal approach to OA pain management
* Is a veterinary device, not a drug

Synovetin OA utilizes the procedure of radiosynoviorthesis (RSO) to break the vicious cycle of pain and inflammation. RSO is a well-established procedure that has been successfully and safely used in humans for more than 60 years. In the RSO procedure, microparticles of Synovetin OA selectively target pro-inflammatory macrophages and synoviocytes in the affected joint which are key sources of inflammation.

Synovetin OA effectiveness and safety were demonstrated in three multi-center studies, showing a 92 percent treatment success rate in dogs with grade 1 and 2 elbow OA. Dogs with grade 3 elbow OA showed 71.4 percent overall treatment success. Pet owners and veterinarians reported up to 12 months of sustained effectiveness.

“This procedure is commonly and safely performed in people,” explained Peter Selover, Exubrion’s chief executive officer. “With the recent NRC guidelines, we expect to have at least 50 veterinary hospitals around the country licensed to use Synovetin in the first half of 2021, offering relief to pets whose pain may not be adequately managed by current therapies, and pet owners who think surgery may be their only option to relieve their dog’s pain.”

More information including the package insert with instructions for use are found at [www.synovetin.com](http://www.synovetin.com).

About Exubrion

Our vision is to forever improve the compassionate care of companion animals. Our name, Exubrion, emerged from the word “exuberance,” which is the quality of being full of energy and excitement. “Exubrion” speaks to our determination to help animals live healthy, active, and pain-free lives.”

1ACVS. Osteoarthritis in dogs. Available at <https://www.acvs.org/small-animal/osteoarthritis-in-dogs>. Accessed July 8, 2019